Global Hospital & Healthcare Management

Pharmaceutical and biotechnology major Wockhardt has launched Midazolam injection in the United States. Wockhardt received this approval from the United States Food & Drug Administration (US FDA) for marketing the preservative-free version injections containing 1 mg/ml and 5mg/ml Midazolam, which is used for treating acute insomnia and anxiety. Wockhardt had earlier received the US FDA approval for the injection containing preservatives. Midazolam is the generic name for the brand Versed. According to IMS, the total market for Midazolam injections in the US is $56 million.

“Sterile products continue to be a priority area for Wockhardt in the US” said Wockhardt Chairman Habil Khorakiwala. “This is our fourth injection ANDA approval in the past two months and the twelfth sterile product overall,” he added.In the prescription generic pharmaceutical market, Wockhardt has been consistently growing market shares for all its products. Wockhardt today markets over fifty-five products in the US.The injections are manufactured at the US FDA certified formulation plant at Waluj, Maharashtra. The product was developed in-house. Wockhardt Limited is a technology-driven global pharmaceutical and biotechnology major with an innovative multi-disciplinary research and development programme. It has 5 research centres and 15 world-class manufacturing plants that are US FDA, MHRA or other global regulatory body approved, dotting various countries and continents. It has end-to-end integrated capabilities for its products, starting with manufacture of the oral and sterile API’s, the dose forms and marketing through its wholly owned subsidiary in the US. Wockhardt has a global footprint including UK, France, Germany, Ireland, USA and employs a multi-ethnic workforce belonging to 14 different nationalities.

Wockhardt Limited
Wockhardt Towers
Bandra Kurla Complex
Bandra (East), Mumbai 400 051, India
Tel.: +91 22 2653 4444
Fax: +91 22 2653 4242
Website: www.wockhardt.com